Updated on 2025/10/28

写真a

 
SANO Yuta
 
Organization
Nagoya University Hospital Urology Assistant Professor
Graduate School
Graduate School of Medicine
Title
Assistant Professor

Research History 2

  1. Nagoya University   Graduate School of Medicine

    2024.4

  2. Nagoya University   Nagoya University Hospital Urology   Assistant Professor

    2022.4

To the head of Research History.▲
 

Papers 15

  1. Efficacy and safety of combination immunotherapy for treating advanced non-clear cell renal cell carcinoma: A multicenter retrospective study in Japan

    Iinuma, K; Sano, Y; Nishikawa, K; Taniguchi, T; Matsuyama, A; Ozawa, K; Ishida, T; Tochigi, K; Tamura, M; Kubota, Y; Akamatsu, S; Inoue, T; Koie, T

    SCIENTIFIC REPORTS   Vol. 15 ( 1 ) page： 35526   2025.10

    　More details

    Language：English   Publisher：Scientific Reports  

    This study aimed to evaluate the outcomes of patients with advanced renal cell carcinoma (aRCC) who were histologically diagnosed with non-clear cell carcinoma (nccRCC) and received combination immunotherapy. Oncological outcomes were compared between patients with non-clear cell RCC (nccRCC group) and those with clear cell RCC (cc-RCC group) who received either immune checkpoint inhibitor (ICI) + ICI combination therapy (ICI + ICI) or ICI + tyrosine kinase inhibitor (TKI) therapy (ICI + TKI). This retrospective study analyzed patients with aRCC who received combination immunotherapy as first-line treatment at 12 institutions between August 2018 and November 2023. The primary endpoint was the comparison of overall survival (OS) between the nccRCC and cc-RCC groups. The secondary endpoints included progression-free survival (PFS) and objective response rate (ORR) in both groups. The median follow–up periods for the nccRCC and cc-RCC groups were 17.7 and 20.4 months, respectively. The median OS was significantly shorter in the nccRCC group compared to the cc-RCC group (27.8 months vs. 62.8 months; p < 0.001). The ORRs in the nccRCC and cc-RCC groups were 52.4% and 63.6%, respectively. Among patients treated with ICI + ICI, the median OS was significantly shorter in the nccRCC group compared to the cc-RCC group (23.5 months vs. 62.8 months; p < 0.001). In the current era of ICI treatment, patients with nccRCC exhibit poorer oncological outcomes than those with cc-RCC. Indications should be evaluated thoroughly before selecting ICI + ICI treatment combinations for these patients.

    DOI： 10.1038/s41598-025-19523-4

    Web of Science

    Scopus

    PubMed

  2. A Case of Malignant Melanoma Metastasis in the Ileal Conduit Open Access

    Shamoto, N; Naito, Y; Sano, Y; Matsuo, K; Inoue, S; Sano, T; Kimura, T; Ishida, S; Matsukawa, Y; Akamatsu, S

    IJU CASE REPORTS   Vol. 8 ( 5 ) page： 485 - 488   2025.9

    　More details

    Language：English   Publisher：Iju Case Reports  

    Introduction: Tumor development in the ileal conduit is rare. Herein, we present a case of metastatic malignant melanoma occurring within the ileal conduit 17 years after radical cystectomy. Case Presentation: A 76-year-old Japanese man, with a history of bladder cancer treated with radical cystectomy and ileal conduit diversion, presented with gross hematuria. He had malignant melanoma diagnosed 10 years prior, with recurrent metastases managed through surgery and adjuvant therapy. During his recent admission, metastases to the subcutaneous tissue and retroperitoneum were noted. Contrast-enhanced computed tomography revealed bilateral hydronephrosis and a tumor in the ileal conduit. Endoscopic resection confirmed metastatic malignant melanoma. The patient's renal function stabilized postoperatively, and hematuria was controlled. A palliative care approach was adopted to treat the melanoma. Conclusion: This rare case of metastatic malignant melanoma within an ileal conduit highlights the importance of histopathological examinations in patients with overlapping malignancies. Trial Registration: 2016-0474.

    DOI： 10.1002/iju5.70073

    Open Access

    Web of Science

    Scopus

    PubMed

  3. A case of non-traumatic rectus sheath hematoma in a post-kidney transplant patient undergoing catheter embolization during anticoagulation treatment for atrial fibrillation Open Access

    Fujieda, K; Saito, S; Tanaka, A; Furuhashi, K; Ozeki, T; Yasuda, Y; Sano, Y; Ishida, S; Maruyama, S

    CEN CASE REPORTS   Vol. 13 ( 6 ) page： 528 - 533   2024.12

    　More details

    Language：English   Publisher：Cen Case Reports  

    A 65-year-old man, a post living donor kidney transplant patient, was admitted to the intensive care unit (ICU) with a severe bacterial infection. He also tested positive for coronavirus disease and had a cough. On admission, heparin was administered for atrial fibrillation. On the third day of hospitalization, his general condition had recovered, and he was discharged from the ICU to the general ward. On the fourth day of hospitalization, he experienced abdominal pain, and a hard mass was palpated in the left lower abdomen. On the fifth day of hospitalization, contrast-enhanced computed tomography showed an extensive rectus sheath hematoma (RSH) extending from the left lower abdominal wall to the left side of the bladder, with extravasation from a small branch of the left inferior epigastric artery. Heparin was discontinued, and transcatheter arterial embolization was performed to control the bleeding. RSH is a rare disease, and cases of extensive hematoma in post-kidney transplant patients occur even less frequently. Patients taking anticoagulants and those with chronic kidney disease are at high risk for RSH, so physicians should be cognizant of this disease when these patients develop abdominal pain.

    DOI： 10.1007/s13730-024-00890-2

    Web of Science

    Scopus

    PubMed

  4. A case of late-onset organizing pneumonia following COVID-19 infection in a post-kidney transplant patient Open Access

    Fujieda, K; Saito, S; Tanaka, A; Furuhashi, K; Yasuda, Y; Sano, Y; Kato, M; Maruyama, S

    CEN CASE REPORTS   Vol. 13 ( 5 ) page： 346 - 350   2024.10

    　More details

    Language：English   Publisher：Cen Case Reports  

    A 50-year-old man who had undergone a living-donor kidney transplant 12 years prior for chronic renal failure due to autosomal dominant polycystic kidney disease contracted coronavirus disease 19 (COVID-19). He had a positive antigen test, mild symptoms, sore throat, and fever of 37.9 ℃. The patient was treated with molnupiravir for 5 days, and the symptoms disappeared 5 days after onset. However, 10 days after onset, he developed a fever of approximately 37 ℃ and a non-productive cough; 27 days after onset, the patient was hospitalized for anorexia and a worsening respiratory condition. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen test results on admission were negative, and no antiviral medications were administered against SARS-CoV-2. Computed tomography revealed extensive ground-glass opacities in both lung fields. The patient was treated with steroid pulse therapy, ceftriaxone, atovaquone, azithromycin, and respiratory management using a high-flow nasal cannula. The combined therapies were successful, and the patient was managed with a nasal oxygen cannula after 3 days. Oxygen administration was discontinued after 6 days of hospitalization, and the patient was discharged after 14 days. Based on the laboratory findings, bacterial, interstitial, and Pneumocystis pneumonia were unlikely. The success of the steroid pulse therapy suggested that respiratory failure was caused by pneumonia due to the immune response after COVID-19 infection.

    DOI： 10.1007/s13730-023-00849-9

    Web of Science

    Scopus

    PubMed

  5. Changes in antibody titer after four and five doses of the SARS-CoV-2 vaccine in Japanese post-kidney transplant patients

    Fujieda, K; Tanaka, A; Kikuchi, R; Takai, N; Saito, S; Yasuda, Y; Sano, Y; Kato, M; Furuhashi, K; Maruyama, S

    THERAPEUTIC APHERESIS AND DIALYSIS   Vol. 28 ( 4 ) page： 489 - 498   2024.8

    　More details

    Language：English   Publisher：Therapeutic Apheresis and Dialysis  

    Introduction: Immunosuppressed patients exhibit low antibody acquisition rates following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Kidney transplant recipients previously exhibited low antibody acquisition rates after two vaccine doses, which increased after the third dose. We evaluated antibody titers of Japanese post-kidney transplant patients after the fourth and fifth vaccinations. Methods: Antibody titers for SARS-CoV-2 spike protein were measured between 3 weeks and 3 months after the fourth or fifth vaccination. Results: Increased antibody acquisition rates were observed after the fourth (75.0% antibody-positive) and fifth (81.5% antibody-positive) vaccinations. The antibody-acquired group after the fourth vaccination exhibited a higher body mass index and estimated glomerular filtration rate (eGFR) than the non-acquired group. A higher eGFR was associated with antibody acquisition after the fifth vaccination. Conclusion: In Japanese post-kidney transplant patients, the antibody acquisition rate increased with each vaccine additional dose. Additional vaccinations are recommended to protect against SARS-CoV-2 infection.

    DOI： 10.1111/1744-9987.14114

    Web of Science

    Scopus

    PubMed

  6. Treatment escalation and de-escalation of de-novo metastatic castration-sensitive prostate cancer

    Akamatsu, S; Naito, Y; Nagayama, J; Sano, Y; Inoue, S; Matsuo, K; Sano, T; Ishida, S; Matsukawa, Y; Kato, M

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 86 ( 2 ) page： 169 - 180   2024.5

    　More details

    Language：English   Publisher：Nagoya Journal of Medical Science  

    Androgen receptor signaling inhibitors combined with androgen deprivation therapy have become the standard of care for metastatic castration-sensitive prostate cancer (mCSPC), regardless of tumor volume or risk. However, survival of approximately one-third of these patients has not improved, necessitating further treatment escalation. On the other hand, for patients with oligometastatic mCSPC, there is an emerging role for local radiation therapy. Although data remain scarce, it is expected that treatment of both primary tumor as well as metastasis-directed therapy may improve survival outcomes. In these patients, systemic therapy may be de-escalated to intermittent therapy. However, precise risk stratification is necessary for risk-based treatment escalation or de-escalation. In addition to risk stratification based on clinical parameters, research has been conducted to incorporate genomic and/or transcriptomic data into risk stratification. In future, an integrated risk model is expected to precisely stratify patients and guide treatment strategies. Here, we first review the transition of the standard treatment for mCSPC over the last decade and further discuss the newest concept of escalating or de-escalating treatment using a multi-modal approach based on the currently available literature.

    DOI： 10.18999/nagjms.86.2.169

    Web of Science

    Scopus

    PubMed

  7. Optimal sequential therapy for metastatic castration-resistant prostate cancer after androgen receptor pathway inhibitors in the up-front era.

    Naito, Y; Nagayama, J; Sano, Y; Inoue, S; Matsuo, K; Sano, T; Ishida, S; Matsukawa, Y; Kato, M; Akamatsu, S

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 42 ( 4_SUPPL ) page： 168 - 168   2024.2

    　More details

  8. Establishment of an adverse effect prevention protocol on plasma exchange using fresh frozen plasma prior to ABO-incompatible living donor kidney transplantation at our hospital

    Tanaka, A; Watanabe, Y; Furuhashi, K; Saito, S; Yasuda, Y; Kosugi, T; Sano, Y; Kato, M; Maruyama, S

    THERAPEUTIC APHERESIS AND DIALYSIS   Vol. 28 ( 1 ) page： 152 - 157   2024.2

    　More details

    Language：English   Publisher：Therapeutic Apheresis and Dialysis  

    Introduction: Simple plasma exchange (PE) with fresh-frozen plasma replacement allows antibody removal for ABO-incompatible living donor kidney transplantation, but is associated with a high incidence of allergic reactions. We developed, implemented, and evaluated a protocol for safe preoperative PE. Methods: The protocol comprised pretreatment (125 mg methylprednisolone infusion, 400 mg acetaminophen and 30 mg diphenhydramine orally) with a replacement fluid rate < 20 mL/min. Allergic reaction incidence was investigated in controls who underwent ABO-incompatible living donor kidney transplantation between 2016 and March 2020 (group C) and patients who underwent the protocol and procedure between April 2020 and February 2023 (group N). Results: Ten (group C) and 19 (group N) patients performed 11 and 30 sessions of PE, respectively. Allergic reactions occurred in 81.8% and 36.7% (p = 0.014), respectively, with an odds ratio of the protocol was 0.056 (95% CI 0.0059–0.5380, P = 0.013). Conclusion: Our protocol resulted in a significantly lower incidence of allergic reactions.

    DOI： 10.1111/1744-9987.14071

    Web of Science

    Scopus

    PubMed

  9. Recent insights on the clinical, pathological, and molecular features of intraductal carcinoma of the prostate Open Access

    Naito, Y; Kato, M; Nagayama, J; Sano, Y; Matsuo, K; Inoue, S; Sano, T; Ishida, S; Matsukawa, Y; Tsuzuki, T; Akamatsu, S

    INTERNATIONAL JOURNAL OF UROLOGY   Vol. 31 ( 1 ) page： 7 - 16   2024.1

    　More details

    Language：English   Publisher：International Journal of Urology  

    Intraductal carcinoma of the prostate, a unique histopathologic entity that is often observed (especially in advanced prostate cancer), is characterized by the proliferation of malignant cells within normal acini or ducts surrounded by a basement membrane. Intraductal carcinoma of the prostate is almost invariably associated with an adjacent high-grade carcinoma and is occasionally observed as an isolated subtype. Intraductal carcinoma of the prostate has been demonstrated to be an independent poor prognostic factor for all stages of cancer, whether localized, de novo metastatic, or castration-resistant. It also has a characteristic genetic profile, including high genomic instability. Recognizing and differentiating it from other pathologies is therefore important in patient management, and morphological diagnostic criteria for intraductal carcinoma of the prostate have been established. This review summarizes and outlines the clinical and pathological features, differential diagnosis, molecular aspects, and management of intraductal carcinoma of the prostate, as described in previous studies. We also present a discussion and future perspectives regarding intraductal carcinoma of the prostate.

    DOI： 10.1111/iju.15299

    Web of Science

    Scopus

    PubMed

  10. 当院における移植後悪性腫瘍の検討

    佐野 優太, 石田 昇平, 佐野 友康, 井上 聡, 木村 友和, 松川 宜久, 尾関 貴哉, 田中 彰仁, 丸山 彰一, 赤松 秀輔

    移植   Vol. 59 ( Supplement ) page： s326_2 - s326_2   2024

    　More details

    Language：Japanese   Publisher：一般社団法人 日本移植学会  

    <p>本邦の2010年～2020年における腎移植レシピエントの死亡原因として悪性腫瘍は第1位(16.6%)であり、免疫抑制下におかれる腎移植患者は悪性腫瘍発生の高リスクとされ、悪性腫瘍の発生状況や対策は重要な課題である。2002年より2022年12月までに当院で施行した腎移植179例を対象としレトロスペクティブに検討した。悪性腫瘍は15例（8.4%）に１７種の癌が発生した。内訳は腎癌5例、大腸癌3例、膵癌2例、子宮体癌１例、前立腺癌1例、膀胱癌1例、胃癌1例、肝細胞癌1例、慢性骨髄性白血病1例、甲状腺癌1例であった。癌発症群は発症なし群と比較して、レシピエント年齢が高く、献腎移植、急性拒絶反応が多く、観察期間が長かった。また癌発症群では生存率が低かったが、生着率（death-censored）には差がなかった。癌発症例のうち癌死は4例（26.7%）であった。全例death with functioning graftであった。腎移植後は悪性腫瘍の発生率が上がり、また死亡率も高く注意が必要である。定期的な健診や予防が推奨される。当院における腎移植後悪性腫瘍の発生状況につき若干の文献的考察を加え報告する。</p>

    DOI： 10.11386/jst.59.supplement_s326_2

    CiNii Research

  11. Efficacy of rehabilitation initiated in the early phase after simultaneous deceased donor liver and kidney transplantation: A case report Open Access

    Tanaka, S; Mizuno, Y; Nojiri, S; Futamura, D; Nagaya, M; Nishida, Y; Sano, Y; Ishida, S; Kato, M; Kurata, N; Jobara, K; Fujimoto, Y; Ogura, Y

    MEDICINE   Vol. 102 ( 38 ) page： e35324   2023.9

    　More details

    Language：English   Publisher：Medicine United States  

    Rationale: The purpose of this case report is to describe a case of successful early rehabilitation intervention for simultaneous liver and kidney transplantation (SLKT). Patient concerns: A 51-year-old Japanese man was diagnosed with Caroli disease 27 years ago. Hemodialysis was introduced due to end-stage renal disease 17 years ago. Diagnoses: After successful SLKT, the patient was extubated on postoperative day (POD) 1, liberated from dialysis on POD 4, and discharged from the intensive care unit on POD 9. Interventions: Supervised rehabilitation was started on POD 2, and the patient was able to walk 100 m on POD 9. Electrical muscle stimulation therapy was started to improve muscle weakness in both legs on POD 16, and aerobic exercise using a cycle-ergometer was started on POD 24. Outcomes: The 6-minute walking distance improved from 324 m on POD 14 to 501 m on POD 28. The patient could walk 4000 to 5000 steps per day at hospital discharge, and was discharged home on POD 32. There were no adverse events, including worsening hepatic or renal function, during the rehabilitation period. One month after discharge, the patient was able to perform 30 to 40 minutes of aerobic exercise every day, and returned to work 5 months after discharge. Lessons: This case shows that early rehabilitation intervention immediately after SLKT safely and rapidly improved physical performance without adverse events. The results in the present case suggest that regular physical assessment and appropriate interventions with a variety of exercise modalities can contribute to improved physical performance in SLKT patients.

    DOI： 10.1097/MD.0000000000035324

    Open Access

    Web of Science

    Scopus

    PubMed

  12. 腎移植後ガンシクロビル耐性サイトメガロウイルス感染となった2例

    佐野 優太, 石田 昇平, 佐野 友康, 加藤 真史, 田中 章仁, 齋藤 尚二, 安田 宜成, 丸山 彰一, 赤松 秀輔

    移植   Vol. 58 ( Supplement ) page： s274_2 - s274_2   2023

    　More details

    Language：Japanese   Publisher：一般社団法人 日本移植学会  

    <p>サイトメガロウイルス(CMV)感染症は最も頻度が高く重要な移植後ウイルス感染症である。治療にはまずガンシクロビル(GCV)、バルガンシクロビル(VGCV)が使用されるが、今回移植後GCV耐性CMV感染となり、ホスカルネットナトリウムにて治癒した2例を経験したので報告する。症例1:50代男性。X-17年より血液透析導入。Caroli病による頻回の胆管炎で入院を繰り返していた。ドナーは50代女性。原疾患は脳出血。脳死下肝腎同時移植施行。S-Cre1.00mg/dl前後で安定し、特記合併症なく術後約一か月で退院となった。CMV抗体陽性。術後7か月後、CMV感染となりVGCV内服開始。内服開始後もCMV感染の改善見られず、GCV耐性が判明しホスカルネットナトリウム投与開始。特記合併症なく治癒した。症例2:40代男性。X年、悪性高血圧による慢性腎不全にて血液透析導入。母親をドナーとした生体腎移植施行。S-Cre2.00mg/dl前後で安定し、特記合併症なく術後約一か月で退院となった。レシピエントCMV抗体陰性、ドナーCMV抗体陽性であったためVGCV予防内服を開始した。術後6か月後、CMV感染となりVGCV内服を治療量へ増やした。内服開始後もCMV感染の改善見られず、GCV耐性が判明しホスカルネットナトリウム投与開始。特記合併症なく治癒した。今回、移植後GCV耐性CMVに対してホスカルネットナトリムを使用し、特記問題なく治癒した症例を経験したので若干の文献的考察を加えて報告する。</p>

    DOI： 10.11386/jst.58.supplement_s274_2

    CiNii Research

  13. 生体腎移植ドナーにおける腎提供後のフォローアップの重要性

    安田 宜成, 田中 章仁, 齋藤 尚二, 加藤 規利, 小杉 智規, 佐野 優太, 加藤 真史, 丸山 彰一

    移植   Vol. 58 ( Supplement ) page： s248_3 - s248_3   2023

    　More details

    Language：Japanese   Publisher：一般社団法人 日本移植学会  

    <p>【目的】日本透析医学会の統計調査では慢性維持透析患者107 人（0.043％）が腎移植ドナーとしての腎提供ありと回答した。名古屋大学の生体腎移植ドナーの予後を調査した。</p><p>【方法】対象は1998年以降に名古屋大学で生体腎移植のため腎提供したドナー167名。内2020～22年に受診した138名の最終診察時のCKD重症度分類を調査した。受診がない29名について背景を調査した。</p><p>【結果】生体腎移植ドナーのGFR区分はG2:18名（13.0％）、G3a:74名（53.6％）、G3b:44名（31.9％）G4:2名（1.5％）、蛋白尿区分はA1:103名（74.6％）、A2:25名（18.1％）、A3:5名（3.6％）、未測定5名（3.6％）であった。G4の1名は73歳男性で腎提供前の2回の実測Ｃｃｒ平均は126.15ｍＬ/分であったが腎提供後に高血圧を合併し、腎提供後15年以上の経過で大動脈瘤手術を受けていた。残る1名は80歳女性で腎提供前の実測GFRは113.9で、腎提供後も10年以上安定していたが、急性腎障害後に腎機能が低下した。A3の4名では、腎提供前の高血圧合併2名、肥満1名だった。</p>

    DOI： 10.11386/jst.58.supplement_s248_3

    CiNii Research

  14. Caroli病(先天性多発肝内胆管拡張症)による難治性胆管炎,末期腎不全症例に肝腎同時移植を実施した1例 Reviewed

    佐野優太

    日本臨床腎移植学会雑誌     2023

    　More details

    Authorship：Lead author   Language：Japanese  

  15. 脳死下肺移植後に生体腎移植を施行した1例

    佐野 優太, 近藤 洋平, 吉澤 賢祐, 中根 渉, 内藤 祐志, 佐野 友康, 松尾 かずな, 石田 昇平, 松川 宣久, 加藤 真史

    移植   Vol. 57 ( Supplement ) page： s371_2 - s371_2   2022

    　More details

    Language：Japanese   Publisher：一般社団法人 日本移植学会  

    <p>レシピエント：40代男性。間質性肺炎のため、X-5年に脳死下両側肺移植施行後。免疫抑制剤としてMMF、TacER、Pred.内服中。徐々に腎機能悪化し、X-1年に血液透析導入。妹をドナーとした生体腎移植目的に当科受診。血液型不一致。AB 2mismatch　DR　1mismatch、CDC　T(-)Bw(-)Bc(-)、FCXM　T(-)B(-)、PRA screening　classⅠ(-)classⅡ(-)、導入免疫抑制剤：TacER+MMF+Pred.+BXM。右腸骨窩生体腎移植術施行。手術時間：3時間52分。外腸骨静脈-腎静脈、外腸骨動脈-腎動脈を吻合。尿管膀胱吻合は粘膜下トンネル3cm作成、Lich-Gregori法で縫合。術後速やかに腎機能発現し、S-Cre1.3mg/dl前後で推移。術後7か月拒絶反応なく、腎機能安定し経過している。両側肺移植後に生体腎移植を施行し、術後経過良好であったので若干の文献的考察を加え報告する。</p>

    DOI： 10.11386/jst.57.supplement_s371_2

    CiNii Research

▼display all

To the head of Papers.▲

Presentations 6

  1. 当院における腎移植後悪性腫瘍の検討

    佐野優太

    第60回　日本移植学会総会  2024.9.14 

    　More details

    Event date： 2024.9

    Presentation type：Poster presentation  

  2. 生体腎移植後早期にT細胞型拒絶反応を起こした1例

    佐野優太

    第39回腎移植・血管外科研究会  2024.6.13 

    　More details

    Event date： 2024.6

    Presentation type：Oral presentation (general)  

  3. A Study of malignant tumors after transplantation in our hospital.

    2024.4.27 

    　More details

    Event date： 2024.4

    Presentation type：Poster presentation  

  4. 腎がん治療指針(2024年) Invited

    佐野優太

    2024.4.12 

    　More details

    Event date： 2024.4

    Language：Japanese   Presentation type：Public lecture, seminar, tutorial, course, or other speech  

  5. 生体腎移植

    佐野優太

    第33回腎移植勉強会  2024.3.16 

    　More details

    Event date： 2024.3

    Presentation type：Public lecture, seminar, tutorial, course, or other speech  

  6. 献腎移植後に急速に進行した固有腎細胞癌の1例

    佐野優太

    第57回　日本臨床腎移植学会  2024.2.14 

    　More details

    Event date： 2024.2

    Presentation type：Oral presentation (general)  

▼display all

To the head of Presentations.▲
 

Teaching Experience (On-campus) 1

  1. 泌尿器科

    2024

To the head of Teaching Experience (On-campus).▲